Abstract
277TiP OASIS 4 study design: A phase III trial assessing the efficacy and safety of elinzanetant in the treatment of vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
